13 D Management LLC Alkermes Plc. Transaction History

13 D Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $222,015 - $263,457	-7,834 Reduced 2.84%	268,250 $8.4 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $2.72 Million - $3.12 Million	-107,500 Reduced 28.03%	276,084 $7.78 Million
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $690,473 - $825,799	-31,471 Reduced 7.58%	383,584 $10 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $680,803 - $787,565	25,788 Added 6.62%	415,055 $12.4 Million
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $793,446 - $962,660	-34,393 Reduced 8.12%	389,267 $10.2 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $556,931 - $832,155	-25,940 Reduced 5.77%	423,660 $9.85 Million
Q2 2021 Aug 16, 2021	BUY	$18.78 - $25.15 $8.44 Million - $11.3 Million	449,600 New	449,600 $11 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of 13 D Management LLC, based on Form 13F filings with the SEC.

Stay updated on 13 D Management LLC with notifications on news.